

GLAXOSMITHKLINE PLC  
Form 6-K  
March 06, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 06 March 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes    No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- |                                       |                                      |
|---------------------------------------|--------------------------------------|
| a) Name                               | Mr S A Hussain                       |
| b) Position/status                    | President, Global<br>Pharmaceuticals |
| c) Initial notification/<br>amendment | Initial Notification                 |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	The sale of 98,581.776 Ordinary Shares on 6 March 2017 at a price of £16.8006.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£16.8006	98,581.776
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2017-03-06	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mrs S G Hussain
b) Position/status	PCA of Mr S A Hussain (President, Global Pharmaceuticals)
c) Initial notification/ amendment	Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
--	--	--

b) Nature of the transaction	The sale of 131,418 Ordinary Shares on 6 March 2017 at a price of £16.835.	
	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.835	131,418
d) Aggregated information Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2017-03-06	
f) Place of the transaction	London Stock Exchange (XLON)	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: March 06, 2017

By: VICTORIA WHYTE

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc